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Alzheimerova choroba je neudegenerativní onemocněmí postihující celou centrální 
nervovou soustavu včetně gliových buněk. Mechanismy tohoto onemocnění stále nejsou zcela 
objasněny, přesto současný výzkum naznačuje, že spolu se známými charakteristickými 
znaky Alzheimerovy choroby, jako je hromadění amyloidu β a hyperfosforylovaného tau, by 
důležitým rysem jak v neuronech, tak v gliových buňkách, především v astrocytech a 
mikrogliích, mohla být dysregulace vnitrobuněčné vápníkové homeostáze. Gliové buňky hrají 
důležitou roli jak ve zdravém mozku, tak během progrese Alzheimerovy choroby. Jejich 
hlavní funkce, jako například podpora neuronů a udržování synapsí, jsou během této nemoci 
narušeny. Současný výzkum naznačuje, že narušená vápníková signalizace gliových buněk 
vyvolaná během Alzheimerovy choroby, by eventuálně mohla podporovat nesprávnou činnost 
těchto buněk a zvýšit jejich zánětlivou reakci, tudíž ovlivňovat neurony a zůsobit poškození 
mozku. Je pravděpodobné, že probíhající zánětlivá reakce a zhoršená vápníková signalizace 
se navzájem ovlivňují a následně urychlují progresi Alzheimerovy choroby. 
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Alzheimer’s disease (AD) is a neurodegenerative disorder affecting the entire central 
nervous system including glial cells. The mechanisms of this disease are not yet entirely clear, 
although recent studies suggest that among the known hallmarks of AD, such as accumulation 
of amyloid β and hyperphosphorylated tau, dysregulation of intracellular calcium homeostasis 
is proposed to be a significant feature both in neurons and glial cells, namely astrocytes and 
microglia. Glial cells play an important role both in healthy brain and during AD progression. 
Their major functions, such as supporting neurons or maintaining synapses, are impaired 
during this disease. Recent findings suggest that aberrant glial calcium signaling activated 
during AD, could possibly promote the malfunction of these cells and increase their 
inflammatory response, thus affecting neurons and causing brain damage. It is likely, that the 
ongoing inflammation and the impaired calcium signaling affect one another, consequently 
enhancing the progression of AD. 
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AD   Alzheimer’s disease 
 AMPA  α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid 
 APP   amyloid precursor protein 
 ATP   adenosine triphosphate 
 Aβ   beta-amyloid 
 CNS   central nervous system 
 CSF   cerebrospinal fluid 
 DAG   1,2-diacylglycerol 
 DICTs  damage-induced Ca
2+
 transients 
 FAD   familial form of Alzheimer’s disease 
 GABA  gamma-aminobutyric acid 
 GPCRs  G-protein coupled receptors 
 IL-1β   interleukin-1 beta 
 IP3   inositol triphosphate 
 IP3R   inositol triphosphate receptor 
 LPS   lipopolysaccharide 
 MCI   mild cognitive impairment 
 mGluR3  metabotropic glutamate receptor type 3 
 mGluR5  metabotropic glutamate receptors type 5 
 NFTs   neurofibrillary tangles 
NLRP3 nucleotide binding and oligomerization domain-like receptor 
family pyrin domain containing 3 
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 NMDA  N-methyl-D-aspartate 
 NO   nitric oxide 
 PHFs   paired helical filaments 
 PIP2   phosphatidylinositol-4,5-bisphosphate 
 PS1   presenilin 1 
 ROS   reactive oxygen species 
 RyR   ryanodine receptor 
 TNF-α  tumor necrosis factor alpha 





Alzheimer’s disease (AD) represents the most common form of dementia among the 
elderly. According to the Delphi consensus study in 2010 an estimated 24 million people had 
dementia with 4,6 million of new cases every year. The number is expected to double every 
20 years up to 81 million in 2040 (Ferri et al., 2010). In 2013 there was approximately 35 
million patients affected by AD (McGeer & McGeer, 2013). Among other risk factors of AD 
age is one of the most relevant. With the increasing life span of today’s population, AD has 
become a significant health issue. The increasing number of cases shows the exponential 
growth of its prevalence with higher age. The fact that there is no known cure or prevention of 
AD together with the high costs of healthcare for AD patients, this disease has become a 
major public health concern of today’s society. 
The aim of the thesis is to give an overview about the major pathological features of 
AD together with the main mouse models used for research of this disease, glial cells as major 
participants in the central nervous system (CNS), their functions and impairment during 
normal aging and AD progression. Importantly, the thesis also focuses on calcium signaling 




Alzheimer’s disease is a form of dementia which mostly impacts people older than 65 
years of age. Dementia as an overall term is defined as a sum of symptoms such as declined 
cognitive and functional abilities, deterioration of memory and in late stages of AD the 
inability to preform everyday activities caused by major neuronal loss in the brain tissue. 
Ultimately, AD patients lose their ability to walk or even swallow and the final stages of 
disease lead to impairment of all basic functions of human body, eventually being fatal. 
During such late stages of AD the patients are bed-bound and entirely dependent on 24/7 care 
(Association, 2014). 
There are two known forms of AD: familial AD with an earlier onset and sporadic AD 
which represents 99% of all cases (Bekris, Yu, Bird, & Tsuang, 2010). Familial AD is caused 
by mutations in one of the 3 known genes, including genes for the amyloid precursor protein,  
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the presenilin 1 and presenilin 2 proteins (Bekris et al., 2010). People having mutations in one 
of these genes are certain to develop AD. Individuals with this familial form incline to express 
AD symptoms before 65 years of age, however, the phenotypes of the familial and sporadic 
forms are practically identical. 
The revised criteria and guidelines for diagnosing AD proposed by the National 
Institute on Aging (NIA) and the Alzheimer’s Association in 2011 recognize three stages of 
this disease; preclinical AD, mild clinical impairment (MCI) and dementia. In the first stage 
(preclinal AD), individuals do not show noticeable AD symptoms such as memory loss or 
cognitive impairment but early brain changes such as beta-amyloid (Aβ) accumulation can be 
identified (Sperling et al., 2011). Such changes may begin 20 years before the first observable 
symptoms of AD occur (Villemagne et al., 2013). Mild cognitive impairment (MCI) is the 
second stage of AD, in which individuals express slight, but recognizable, changes in thinking 
abilities, nevertheless, not yet affecting their performance of everyday activities (Albert et al., 
2011). Dementia due to AD is the third and final stage. This stage leads to major cognitive 
impairment, which causes the inability to preform basic daily routines (McKhann et al., 
2011). Nevertheless, an additional research is needed to validate these 2011 criteria, hence 
they yet cannot be used for clinical diagnosis (Association, 2014). 
 
Pathophysiology 
The neuropathology of AD is characterized by extracellular accumulation of beta-
amyloid (Aβ) in the form of Aβ-plaques (also called senile or neuritic plaques) and the 
appearance of neurofibrillary tangles (NFTs). 
The formation of amyloid plaques is a result of extracellular Aβ deposition, which is a 
product of alternative splicing of the amyloid precursor protein (APP). APP is cleaved by 
specific secretases into Aβ(1-40) or Aβ(1-42), the latter being more prone to self-aggregation 
(Citron et al., 1996). Aβ deposits form the core of the complex radial structure of amyloid 
plaques. This core is surrounded by dystrophic neurites and on the periphery several microglia 
and reactive astrocytes are commonly encountered (Dickson, 1997). Although considered as a 
substantial factor causing neuronal loss during AD, amyloid plaques can be found in the 
cortex of normally aging elderly subjects in absence of any signs of dementia, thus it is only 




Figure 1 – The amyloid cascade hypothesis. Amyloid precursor protein (APP) is cleaved into 
Aβ forming intracellular and extracellular deposits, the latter forming Aβ plaques (Ballard et al., 
2011). 
 
Neurofibrillary tangles (NFTs) are composed of clustered structures of paired helical 
filaments (PHFs), which can be found mainly in the regions of the hippocampus, entorrhinal 
cortex, and amygdala. These abnormal structures form a compact filamentous network which 
is generated by self-aggregation of hyper-phosphorylated forms of the tau protein that belongs 
to microtubule-associated proteins. In a healthy brain the tau protein participates in the 
assembly of microtubules, their stabilization and bridging with other cytoskeletal filaments. 
Therefore, it plays a major role in cytoskeletal stabilization and consequently axonal 
morphology. The hyper-phosphorylation, which is caused by diverse protein kinase and 
phosphatase systems, results in structural and conformational changes of the tau protein and 
affects its ability of proper binding with tubulin and microtubular assembly (Dickson, 1997) . 
Even though neurofibrillary tangles and amyloid plaques are the major pathological 
hallmarks of AD there are several other factors considered as possible causes of 




Figure 2 – Amyloid plaques (black arrow) and neurofibrillary tangles (red arrow) stained in 
brain tissue of an AD patient. Visualized by Bielschowski staining, 40x magnified. (Perl, 2010) 
 
Transgenic mouse models 
Transgenic mouse models are the key tool to current research in AD. Although various 
forms of these models have been generated, none of them expresses complete AD symptoms. 
The finding of mutations causing the familial form of AD (FAD) greatly improved the 
transgenic AD mouse modeling. Before this discovery there were attempts of overexpressing 
wild-type APP in transgenic mice, however there were no amyloid plaques or NFTs observed 
(Elder, Sosa, & Gasperi, 2010). 
After the finding of FAD mutations new animal models were developed on the basis 
of overexpressing mutated transgenes typical for FAD onset. The first model generated using 
this approach is termed PDAPP  (Games et al., 1995). Mice in this line exhibit age-related 
amyloid plaques with dense cores, dystrophic neurites, reactive astrocytes and activated 
microglia. However, the most widely studied transgenic AD model has been the Tg2576 
mouse line overexpressing the Swedish FAD mutation (Hsiao et al., 1996). Despite the 
extensive amyloid deposition, none of these mouse lines displayed neuronal loss or NFTs. In 
order to enhance neuronal loss double transgenic models have been developed combining the 
presenilin 1 (PS1) and APP mutations (Holcomb et al., 1998). 
In addition, new mouse models have been produced by combing FAD mutations with 
mutant forms of tau, which are found in a different form of dementia and result in formation 
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of NFTs (Lewis et al., 2001). The triple transgenic mouse model (3xTg-AD) characterized by 
overexpression of APP, tau and PS1 transgenes expresses both amyloid plaques and NFTs 
functionally leading to age-dependent synaptic loss (Oddo et al., 2003). 
Transgenic mouse models of AD currently play a substantial role in developing 
potential immunotherapies for AD treatment. The following table contains an overview of 
transgenic mouse models of AD (Table 1). 
 
Table 1 – Overview of main transgenic AD mouse models with their neuropathological 




For a long time glial cells were considered as the supportive cells of the central 
nervous system (CNS), however the current glia-oriented research reveals that glial cells are 
essential for proper neuronal functioning of neurons. Although they do not directly take part 
in synaptic interactions and electrical signaling, glial cells support the defining of synaptic 
contacts and signaling abilities. Among other the core supportive roles of glial cells are 
maintaining the ion/neurotransmitter homeostasis in CNS, providing physical support to 
neurons during neural development, responding to injury, participating in the blood-brain 
barrier, regulating the uptake of neurotransmitters in synapses, exchanging metabolites with 
neurons and insulating nervous pathways. Unlike neurons glial cells have retained the ability 
of mitosis and as stem cells they participate in gliogenesis and neurogenesis (Rodríguez & 
Verkhratsky, 2011), also their membrane comprises various ion channels, receptors and 










The four known types of glial cells in the CNS are astrocytes, microglia, 
oligodendrocytes and NG2 glia also called synantocytes. 
 
Astrocytes 
Besides their structural function astrocytes play a key role in providing suitable 
environment for neurons and they participate in neuronal synaptic connections. Astrocytes 
express functional neurotransmitter receptors and transporters, thus strongly contributing to 
neurotransmitter homeostasis. Other major functions of astrocytes include the formation of 
the blood-brain barrier, regulating the cerebral blood-flow and metabolic supply for neurons 
(Magistretti, 2006). Furthermore, astrocytes have the ability to integrate and respond to 
excitatory external inputs by generating Ca
2+
 oscillations and to release gliotransmitters, thus 




Figure 3 – Organization of astrocytes and neurons in rat cortex. Neurons are labeled blue by 
MAP-2 and astrocytes are labeled yellow by eGFP (Nedergaard, Ransom, & Goldman, 2003). 
 
Morphologically astrocytes are divided into two major types. Fibrous astrocytes have 
long unbranched processes and are found primarily in white matter. Protoplasmic astrocytes 
are located mainly in gray matter and their processes are short and highly branched (Miller & 
Raff, 1984). During the process of aging the ability of astrocytes to protect neurons is 
diminished. During aging the Ca
2+
 homeostasis is disrupted in astrocytes and the Ca
2+
 
signaling dynamics are noticeably faster due to decreased mitochondrial Ca
2+
 uptake. 
Astrocytes of aged CNS are also more sensitive to oxidative stress, which further contributes 
to the aging process (Lin et al., 2007). 
In AD the occurrence of amyloid plaques is associated with the presence of reactive 
astrocytes. This specific glial reaction caused by acute or chronic brain insults is generally 
known as reactive astrogliosis during which astrocytes undergo morphological and functional 
changes. In severe cases the newly proliferated astrocytes form a glial scar in the brain tissue 
(Sofroniew, 2009). Via glutamate transporter reversal or enhanced gliotransmission, reactive 
astrocytes increase neurotoxic molecules, such as glutamate, in extracellular space, and 
resulting glutamate cytotoxicity leads to neuronal loss. In AD reactive astrocytes lose their 
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neuroprotective functions and more importantly, they even contribute to the progress of the 
disease. Likewise, neurotransmitter homeostasis and metabolic exchange can be impaired due 
to changes in reactive astrocytes (Heneka et al., 2010). In proximate astrocytes Aβ deposits 
cause spontaneous Ca
2+
 signaling and changes in Ca
2+
 oscillations. Reactive astrocytes also 
participate in neuroinflammation by releasing proinflammatory molecules such as cytokines 
and reactive oxygen species (ROS) (Verkhratsky et al., 2010). Astrocytes distant to amyloid 
plaques become atrophic as a result of losing their processes. This leads to synaptic loss, 
which underlies cognitive impairment in early stages of AD (Yeh et al., 2011). 
 
 
Figure 4 – Activated astrocytes surrounding Aβ plaques in a double immunostained brain 
section of a 70 year old AD patient. Astrocytes are stained by antibody against glial fibrillary acidic 




Figure 5 – Confocal micrographs from 12 months old mouse models comparing astrocytes 
under physiological conditions/aging (A,C) and astrocytes from 3xTg-AD mouse models (B,D). The 
images show atrophy of  astrocytes distant from amyloid plaques by losing processes (B) and 
astrocytes undergoing astrogliosis in the vicinity of Aβ plaques (labeled red) (D) (Heneka et al., 2010). 
 
Microglia 
Microglia represent the core effectors of the immune system in the CNS. They 
function as local macrophages, hence in their activated state microglia have the ability of 
phagocytosis and they are able to proliferate and migrate to injured or infected locations. 
Activated microglia also release proteolytic enzymes, chemokines, cytokines, complement 
proteins and various other molecules affecting astrocytes and other microglia during 
neuroinflammation (Ransohoff & Perry, 2009). 
Resting microglia in the mature brain have a relatively small cell soma with a number 
of thin branched processes (J J Rodríguez et al., 2010). Each microglial cell in its non-
activated state scans the microenvironment of its anatomical domain. Importantly, these 
domains are strictly bounded and non-overlapping (Heneka et al., 2010). 
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Microglia undergo various changes during aging. The total number and density of 
microglia increase with age, perhaps to compensate their impaired protective functions. 
Senescent microglia have decreased motility and ability of migration, altered production and 
release of pro-inflammatory factors and impaired ability of degrading phagocytized material 
(Mosher & Wyss-Coray, 2014). 
Microglia in AD can have neuroprotective functions in the early stages of the disease 
due to their ability to phagocytize Aβ. However during the progression of AD the struggle of 
microglia to digest the massive quantity of Aβ possibly promotes the neuroinflammation 
processes (Lue, Walker, & Rogers, 2001). In later stages of AD, uncontrolled inflammation 
caused by over-activated microglia result in promoting Aβ aggregation and neuronal loss. 
Moreover, pro-inflammatory cytokines released by microglia can also modify specific kinases 




Figure 6 – Activated microglia in the vicinity of Aβ plaques. Aβ stained brown and microglial 




Besides the well-known function of myelination of neuronal axons oligodendrocytes 
have several other important roles. They are responsible for sodium channel clustering along 
axon segments necessary for generating action potentials and also appear to be essential for 
proper axonal transport and microtubule levels. Furthermore, oligodendrocytes provide 
trophic support for neuronal somas (McTigue & Tripathi, 2008). 
Morphologically oligodendrocytes are cells with many branched processes and upon 
terminal differentiation they extend numerous parallel processes to ensheathe and myelinate 
neuronal axons (Osterhout, 1999). 
During aging several changes in myelin sheaths occur, such as forming dense 
cytoplasm regions and so called “balloons”. These changes both indicate the signs of myelin 
degeneration. On the other hand, surprisingly, myelin production appears not to be impaired 
during aging (Peters, 2003). 
During AD progression oligodendrocytic membranes might be aberrated by Aβ due to 
its ability to damage membranes rich in cholesterol (Roth et al., 2005). This would result in 
diminishing the capability of oligodendrocytes to form myelin sheaths, thus affecting the 
conduction of axonal signals and eventually leading to neurodegeneration (Horiuchi et al., 
2012). Furthermore, by losing the trophic support from oligodendrocytes neurons become 
more vulnerable to damage and neuroinflammation (Roth et al., 2005). 
 
 




Synantocytes, also referred to as polydendrocytes or NG2 cells, are a recently 
discovered type of glial cells with the function of progenitor cells. Synantocytes are able to 
generate oligodendrocytes, astrocytes (Zhu, Bergles, & Nishiyama, 2008) and possibly even 
neurons (Rivers et al., 2008). They also might participate in stabilizing synapses and guiding 
axonal growth (A. M. Butt et al., 2005). The number of synantocytes increases during injury 
and infection due to their capability of proliferation, thus being able to produce new astrocytes 
and oligodendrocytes (Levine, Reynolds, & Fawcett, 2001). 
Synantocytes are morphologically described as cells with a central soma and 
numerous processes slightly overlapping between nearby synantocytes. In gray matter the 
processes integrate with neuronal synapses. 
 
 
 Figure 8 – Immunofluorescence images showing NG2 glia in contact with neurons 
and astrocytes. Double immunofluorescence labelling NG2 (green), neurons (red) with calbindin (A-
C) and astrocytes (red) with glial fibrillary acidic protein (D-E). Scale 50 µm (A,D) and 12,5 µm 
(B,C,E) (A. M. Butt et al., 2005). 
15 
 
Synantocytes play a key role in remyelination (Levine & Reynolds, 1999), hence their 
diminished capacity for regenerating oligodendrocytes is proposed to be a critical factor 
causing myelin loss in the aging brain (A. Butt, 2014). 
In the early stages of AD, synantocytes display atrophic changes, furthermore, with 
the progression of the disease they appear to become hypertrophic and are closely related to 
Aβ deposits. Importantly, the proliferation of synantocytes might be impaired, thus inducing 
enhanced myelin loss in AD (A. Butt, 2014). 
 
Calcium signaling during Alzheimer’s disease 
Calcium homeostasis in the nervous system is essential for appropriate functioning of 
the brain. Therefore, dysregulation of calcium homeostasis and thus disruption of calcium 
signaling is proposed to be one of the common proximal causes of neurodegeneration and 
neuronal dysfunction during aging and AD (Khachaturian, 1994). According to the “calcium 
hypothesis of brain aging and Alzheimer’s disease”, the dysregulation of intracellular calcium 
homeostasis characterizes one of the earliest hallmarks of AD (Khachaturian, 1994). 
Disturbance in neuronal calcium signaling occurs preceding to the advancement of 
histopathological markers and clinical symptoms (LaFerla, 2002); however, it is not yet clear 
if dysregulation of calcium homeostasis could be the primary cause of AD-related 
pathological features. 
Intracellular calcium signaling affects many crucial physiological functions including 
gene expression, initiation of apoptosis, cell differentiation or neurotransmitter release 
(Berridge, Bootman, & Roderick, 2003), therefore calcium homeostasis must be strictly 
regulated. Importantly, any disruption of this balance may result in cell degeneration and 
dysfunction. Furthermore the hypothesis suggests that dysregulation of the intracellular 
calcium homeostasis might lead to age-related functional changes in brain cells, hence 
aberrant calcium signaling could be a common sign of aging and AD (Khachaturian, 1994). 
Recent studies suggest that dysregulation of calcium homeostasis does not reflect only 
to neurons, but inflicts all cell types of the nervous system (McLarnon, Choi, Lue, Walker, & 
Kim, 2005). The inflammatory response of astrocytes and microglia is significantly affected 
by aberrant calcium signaling activated during AD, consecutively resulting in impaired 
calcium homeostasis of neurons and thus affecting proper brain functions. These interactions 
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between altered calcium signaling and the inflammatory responses of glial cells are thought as 
one of the factors increasing the progression of AD (Brawek & Garaschuk, 2014). For 
example, activated glial cells produce pro-inflammatory cytokines, which affect neuronal 
calcium signaling by modifying their voltage-sensitive Ca
2+
 channels, N-methyl-D-aspartate 
(NMDA) receptors, inositol triphosphate receptors (IP3R), ryanodine receptors (RyR) and 
other Ca
2+
-dependent receptors (Halassa & Haydon, 2010; Sama & Norris, 2013). Moreover 
the production and release of the cytokines itself is regulated by Ca
2+
 signaling (Lee et al., 
2012). 
 
Figure 10 – Scheme showing various calcium channels expressed on surface of an astrocyte 
responsible for maintaining calcium signaling and homeostasis. Calcium release from internal stores is 
triggered mainly by the phospholipase C pathway activated by G-protein coupled receptors (GPCRs). 
Phosphatidylinositol-4,5-bisphosphate (PIP2) breaks down into 1,2-diacylglycerol (DAG) and inositol 
triphosphate (IP3), which may trigger calcium release from the endoplasmic reticulum by activating 
IP3 receptors on its surface. P2Y purinergic receptors and metabotropic glutamate receptors type 3 and 
5 (mGluR3, mGluR5) are the major types of GPCRs in astrocytes (Achour et al., 2010). 
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Impaired calcium signaling in astrocytes 
In astrocytes calcium affects many important physiological functions including 
responses to neurotransmitters (Fields, 2000; Haydon, 2001), regulation of gene expression 
(Neary, 2000) and the release of ATP, glutamate and other gliotransmitters (Jeftinija et al., 
1996). Furthermore, astrocytes can impact neurons by generating intercellular calcium waves 
that transfer signals, which can modify their activity and survival (Blanc, Bruce-Keller, & 
Mattson, 1998). During AD, calcium signaling of astrocytes is impaired or altered by their 
activation in the vicinity of Aβ deposits (Mattson & Chan, 2003). 
In a sub-group of cultured astrocytes, exposure to Aβ(1-42) causes Ca
2+
 to enter the 
cells from the extracellular space, thus increasing basal intracellular calcium concentration 
([Ca
2+
]i). Plaque-associated astrocytes also appear to upregulate the expression of inositol-3-
phosphate receptors (IP3R) and glutamate receptor mGluR5 (Grolla et al., 2013; Lim et al., 
2013). MGluR5 is a metabotropic receptor, of which activation leads to Ca
2+
 release from 
intracellular stores. In a healthy adult brain its expression is downregulated (Sun et al., 2013), 
hence the increase during AD may cause disruption of calcium homeostasis in astrocytes. 
 Similarly, spontaneous Ca
2+
 oscillations induced by ATP are largely increased in 
3xTg-AD mouse models in comparison with control mice of the same age (Grolla et al., 
2013). The data from these studies hence propose that calcium signaling in astrocytes during 
AD is amplified. Importantly, the Ca
2+
 oscillations evoked by Aβ triggers the death of 
neurons which have been co-cultured with the astrocytes, thus suggesting that neurotoxicity 
might be a result of impaired astrocytic Ca
2+
 signaling (Abramov et al., 2003). 
In a healthy brain, spontaneous Ca
2+
 oscillations are considered as a form of 
communication between astrocytic and neuronal networks (Hirase et al., 2004; Nimmerjahn, 
2009), hence aging and other pathological processes including AD noticeably alter astrocytic 
calcium signaling. Higher frequency of spontaneous Ca
2+
 oscillations has been observed in 
Bergman glia, the astrocytes of the cerebellum, due to aging (Mathiesen et al., 2013). 
Likewise, the frequency and synchronicity of Ca
2+
 oscillations increase in astrocytes of 
amyloid-depositing mice (Grienberger et al., 2012; Kuchibhotla et al., 2009). Moreover, 






 signaling in reactive astrocytes is likely to affect other glial cells and 
neurons due to the fact that the release of gliotransmitters and inflammatory factors such as 
cytokines depends on Ca
2+
 signals (Volterra & Meldolesi, 2005). Gliotransmitters such as 
ATP, glutamate and D-serine impact neuronal activity, thus increased release of these factors 
can result in the hyperactivity of neurons during AD (Brawek & Garaschuk, 2014). Moreover, 
ATP stimulates the activation of astrocytic P2Y1 receptors which are known to induce the 
release of another gliotransmitter, glutamate (Pascual et al., 2012), and cytokines such as 
tumor necrosis factor alpha (TNF-α; Domercq et al., 2006), hence acting as a signal of 
positive feedback. Furthermore, TNF-α evokes the release of glutamate, thus enhanced release 
of TNF-α significantly amplifies the release of glutamate, which is likely to cause neuronal 
damage (Bezzi et al., 2001). Importantly, increased release of TNF-α and thus glutamate 
occurs in astrocytes in the vicinity of activated microglia. On the contrary, the presence of Aβ 
deposits decreases the glutamate release caused by TNF-α (Rossi et al., 2005), yet the 
mechanism of this process is not utterly clarified. 
Moreover, TNF-α released form reactive astrocytes during AD is assumed to increase 
neuronal excitability, since mice treated with TNF-α infusions following peripheral 
inflammation are more susceptible to seizure (Riazi et al., 2008). TNF-α is also thought to 
enhance the expression of α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) 
receptors on the cell surface of neurons, which are more permeable to Ca
2+
 (Ogoshi et al., 
2005). Hence the higher permeability of AMPA receptors results in extra Ca
2+
 inflow to the 
cell, therefore possibly affecting gene expression and causing cytotoxicity of neurons (Galic, 
Riazi, & Pittman, 2012). Similarly, the increased release of TNF-α results in processes such as 
endocytosis of GABAA receptors and modifying glutamate uptake in glial cells (Galic et al., 
2012), which both affect neuronal activity.  
In vivo higher excitability of neurons has been observed also as a result of enhanced 
release of the cytokine interleukin-1 (IL-1β) from astrocytes (Rodgers et al., 2009), 
furthermore increased concentration of IL-1β in the brain is linked with the susceptibility to 
seizures (Allan & Rothwell, 2001). 
AD-associated neuronal hyperactivity caused by reactive astrocytes could also be 
contributed to by changes of extracellular Ca
2+
 levels (Brawek & Garaschuk, 2014). The 
concentration of extracellular Ca
2+
 decreases due to higher neuronal activity as a result of 
activating voltage-gated Ca
2+
 channels and ionotropic glutamate receptors causing astrocytes 
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to release ATP (Torres et al., 2012). Therefore, the increased levels of extracellular ATP 
induce astrocytic Ca
2+
 waves affecting neuronal activity (Kuchibhotla et al., 2009). 
Taken together, the alterations of astrocytic Ca
2+
 signaling can be caused by Aβ-
deposits, increased release of gliotransmitters and cytokines such as glutamate, ATP, TNF-α 
and IL-1β and likewise by lower extracellular calcium levels caused by enhanced neuronal 
activity. Henceforth the enhanced levels of gliotransmitters and cytokines may result in 
neuronal hyperactivity, neurodegeneration, seizures and furthermore a significantly stronger 
microglial and astrocytic inflammatory response. 
 
Impaired calcium signaling in microglia 
During AD microglia surround Aβ-plaques shortly after their deposition (Meyer-
Luehmann et al., 2008) and similarly to astrocytes become activated (Itagaki et al., 1989). 
Activated microglia release pro-inflammatory factors which can affect astrocytes and neurons 
in the vicinity of the plaques, therefore possibly resulting in aberrant Ca
2+
 signaling of these 
cells (Eichhoff et al., 2011). Recent in vitro studies show that during AD impaired Ca
2+
 
signaling does not impact merely reactive astrocytes and neurons, however, likewise affects 
activated microglia. Compared to microglial cells isolated from healthy patients, intracellular 
Ca
2+
 concentrations occur to be increased in microglia from the AD-affected individuals 
(McLarnon et al., 2005). Likewise, higher levels of intracellular Ca
2+ 
concentration appearing 
together with a decline of agonist-induced Ca
2+
 signals, has been observed in cultured murine 
microglia treated with lipopolysaccharide (LPS)-mediated activation (Hoffmann et al., 2003).  
According to a recent study comparing the responds of resting and activated microglia 
to ATP and substance P, activated microglia appear to have enhanced Ca
2+
 signals reacting to 
these signaling molecules (Seifert et al., 2011). Thus, suggesting that one of the notable 
features of activated microglia during AD is the increase of Ca
2+
 signaling. Importantly, the 
concentration of intracellular Ca
2+
 significantly affects the release of pro-inflammatory 
factors, for instance nitric oxide (NO) and several cytokines are released in response to higher 
levels of intracellular Ca
2+
, according to a study of LPS-activated cultured microglial cells 
(Hoffmann et al., 2003). 
Similarly to astrocytes, the release of the pro-inflammatory cytokine TNF-α in 
microglia also depends on Ca
2+
 signaling. In cultured microglia TNF-α is released as a result 
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of activating P2 receptors (Ikeda et al., 2013). Importantly, microglial cells initiate the 
inflammatory-response by releasing pro-inflammatory mediators such as TNF-α, glutamate or 
ATP, which furthermore affect astrocytic and neuronal activity (Eichhoff et al., 2011). 
Due to presence of damaged neuronal cells, Ca
2+
 oscillations known as damage-
induced Ca
2+
 transients (DICTs) are induced in microglia (Eichhoff et al., 2011) and such 
DICTs may be a result of P2Y receptor activity, which is induced by ATP released from 
damaged cells (Brawek & Garaschuk, 2014). ATP serves as a signaling molecule in both 
healthy and damaged cells; hence higher levels of extracellular ATP suggest pathological 
features, such as disrupted cell membrane, inflammation or stress (Trautmann, 2009). During 
inflammation and activation of microglia the release of ATP is increased due to enhanced 
Ca
2+
 signaling (Imura et al., 2013). Therefore, higher levels of extracellular ATP might be 
considered as one of the attributes of AD and aging (Eichhoff et al., 2011). Increased release 
of ATP during AD results both in basic microglial inflammatory processes (Di Virgilio et al., 
2009) and also in amplifying microglial Ca
2+ 
signaling. Latter caused by the variety of P2 
receptors expressed on their surface (Eichhoff et al., 2011). 
Importantly, also the expression of various P2 receptors is enhanced in activated 
microglia. Upregulation of the P2X7 receptor has been observed in human Aβ-associated 
microglia from individuals with AD, as well as in cells isolated from the brains of Tg2576 
mice (Parvathenani et al., 2003) and likewise in hippocampal microglial cells of AD mouse 
models treated with Aβ(1-42) injections (McLarnon et al., 2006). In summary, increased Ca
2+
 
signaling in microglia both agonist-induced as well as spontaneous might possibly be viewed 
as an important hallmark of aging and likewise various types of dementia including AD, 
together with the fact that higher levels of extracellular ATP have a key role in this 
pathological feature (Brawek & Garaschuk, 2014). 
In addition, increased extracellular ATP levels can cause activation of a protein 
complex known as the nucleotide binding and oligomerization domain-like receptor family 
pyrin domain containing 3 (NLRP3) inflammasome as a result of enhanced intracellular 
calcium release caused by the activation of P2X7 receptors (Murakami et al., 2012). This 
particular inflammasome is responsible for the release of pro-inflammatory cytokines such as 
IL-1β and IL-18 by activating caspase-1, which causes the cleavage of these cytokines into 
their mature forms, thus, contributing to the inflammatory response of microglial cells 
(Franchi et al., 2009). Likewise, the NLRP3 inflammasome is also activated by Aβ (Halle et 
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al., 2008) and interestingly, enhanced activation of NLRP3 can be observed in microglia 
found in the vicinity of Aβ-plaques in an AD mouse model (Heneka et al., 2013). Assuming 
the fact that NLRP activation is prompted by releasing Ca
2+
 from intracellular stores of the 
cell, together with the possible impact of Aβ-deposits, activated microglia during AD are 
thought to show higher levels of intracellular Ca
2+
. Henceforth, enhanced activation of 
NLRP3 could lead to increased release of the cytokines affected by this inflammasome, and 
consequently, it may result in the hyperactivity observed in neurons during AD (Galic et al., 
2012).  
 
 Figure 11 – Illustrative scheme of network wide calcium homeostasis dysregulation during 
AD showing how astrocytes, microglia and neurons affect each other in the presence of Aβ deposits 
(Brawek & Garaschuk, 2014; Eichhoff et al., 2011).  
 
Oligodendrocytes and NG2 glia 
The mechanisms of impaired calcium signaling in oligodendrocytes during AD are not 
yet entirely clear, hence recent studies suggest that aberration of calcium homeostasis in 
oligodendrocytes can contribute to axon demyelization and moreover glutamate induced cell 
death. A recent study shows that increased resting intracellular calcium levels occur in PS1 
mutant mice compared with wild-type mice. Furthermore, oligodendrocytes isolated from 
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these mouse models are more prone to Aβ and glutamate damage. Degeneration of 
oligodendrocytes triggered by calcium homeostasis disruption may lead to axonal dysfunction 
and contribute to cognitive impairment during AD (Pak, Chan, & Mattson, 2003). Generally, 
oligodendrocytes express ionotropic glutamate receptors, especially Ca
2+
-permeable AMPA 
and NMDA receptors and their activation in the presence of increased glutamate levels might 
result demyelization. NMDA receptors are specifically present in the myelinating processes of 
oligodendrocytes, in which the small intracellular space may result in a large increases in 
intracellular ion concentration in response to receptor activation and thus lead to 
disintegration of myelin and oligodendrocytic processes (Káradóttir et al., 2005). 
Until now, there are no data about polydendrocyte pathophysiology in AD 
progression, which is not that surprising because these cells were discovered quite recently 
and ongoing polydendrocyte-oriented research is mostly focused on their functions in CNS 
under physiological conditions or their differentiation potential following various types of 
CNS injuries. Recent findings of Nielsen and colleagues (Nielsen et al., 2013) revealed that 
both oligomeric and fibrillar Aβ(1-42) induced changes in NG2 cell morphology and that in 
vitro exposure to fibrillary Aβ(1-42) decreased the NG2 concentrations in both cell lysates 
and supernatants. Comparing to non-demented individuals they also found significantly 
decreased levels of soluble NG2 in the cerebrospinal fluid (CSF) from clinically diagnosed 
AD patients and that the CSF NG2 levels significantly correlated with the core AD 
biomarkers Aβ(1-42), T-tau and P-tau. 
 
Conclusion 
Glial cells in a healthy brain sustain various crucial roles contributing to the right 
functioning of the central nervous system. For instance, they maintain synaptic contacts, 
provide support for neurons, insulate nervous pathways, participate in the blood-brain barrier 
and preserve homeostasis in the CNS. Importantly, glial cells play a major role in the immune 
response to brain damage or disease by triggering inflammation processes. Most of these 
essential functions are impaired during AD especially the inflammation response. Glial cells, 
primarily astrocytes and microglia, are affected in the presence of Aβ deposits by 
hyperactivation, causing increased inflammation and possibly neuronal damage or death. 
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A significant feature of AD-related malfunctioning of glial cells is dysregulation of 
their calcium homeostasis. Cells affected by Aβ show increased levels of intracellular calcium 
concentrations, thus resulting in aberrant calcium signaling affecting neurons and other glial 
cells. This process supports AD progression by enhancing the glial inflammatory response 
and causing hyperactivity of neurons. Therefore, the calcium hypothesis of AD is suggested to 
bring together the amyloid cascade hypothesis and the inflammation cascade hypothesis 
creating a meaningful link. Above all, since there is no known cure for AD, treating the 
calcium homeostasis of glial cells by for example stabilizing their intracellular calcium 
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